HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

L Lorefice Selected Research

Multiple Sclerosis

2/2022Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?
1/2022Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
4/2021Event-related potentials and deep grey matter atrophy in multiple sclerosis: Exploring the possible associations with cognition.
12/2018Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers.
1/2018Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment.
8/2016Combining HLA-DRB1-DQB1 and Mycobacterium Avium Subspecies Paratubercolosis (MAP) antibodies in Sardinian multiple sclerosis patients: associated or independent risk factors?
11/2015Walking improvements with nabiximols in patients with multiple sclerosis.
1/2015Induction and escalation therapies in multiple sclerosis.
9/2009Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


L Lorefice Research Topics

Disease

9Multiple Sclerosis
02/2022 - 09/2009
3Relapsing-Remitting Multiple Sclerosis
05/2016 - 09/2007
1Autoimmune Diseases (Autoimmune Disease)
02/2022
1Nervous System Diseases (Neurological Disorders)
02/2022
1Cognitive Dysfunction
04/2021
1Infections
05/2016
1Flushing
05/2016
1Neurodegenerative Diseases (Neurodegenerative Disease)
10/2015
1Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
10/2015
1Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar)
10/2015

Drug/Important Bio-Agent (IBA)

2Biomarkers (Surrogate Marker)IBA
02/2022 - 04/2021
2Mitoxantrone (Novantrone)FDA LinkGeneric
01/2018 - 09/2007
2HLA Antigens (Human Leukocyte Antigens)IBA
08/2016 - 09/2009
1alpha-Linolenic Acid (Linolenic Acid)IBA
02/2022
1Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
02/2022
1teriflunomideIBA
01/2022
1amsonic acid (DAS)IBA
12/2018
1AntibodiesIBA
08/2016
1Dimethyl FumarateIBA
05/2016
1Irritants (Vesicants)IBA
05/2016
1nabiximols (Sativex)IBA
11/2015
1DNA-Binding Proteins (DNA Binding Protein)IBA
10/2015
1Natalizumab (Tysabri)FDA Link
01/2011
1chlorbensideIBA
09/2007

Therapy/Procedure

2Therapeutics
01/2018 - 01/2015
1Fecal Microbiota Transplantation
02/2022
1Caloric Restriction
02/2022